
Sangamo Therapeutics SGMO
Sangamo Therapeutics Operating Expenses | SGMO
Annual Operating Expenses Sangamo Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 161 M | 162 M | 450 M | 313 M | 294 M | 248 M | 208 M | 162 M | 92.9 M | 91.9 M | 86.4 M | 72.4 M | 50.8 M | 43.9 M | 46.1 M | 45.7 M | 41.6 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 450 M | 41.6 M | 151 M |
Quarterly Operating Expenses Sangamo Therapeutics
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 33.4 M | 36.1 M | 36.2 M | 36.1 M | 38.8 M | 37.4 M | 52 M | 116 M | 130 M | 140 M | - | 81.4 M | 75.1 M | 73.5 M | - | 77 M | 76.6 M | 72.6 M | 69.2 M | 61.5 M | 59.4 M | 57.6 M | 53.4 M | 51.2 M | 51.1 M | 52 M | 47.6 M | 39.8 M | 40.6 M | 33.6 M | 26.8 M | 24.8 M | 21 M | 20.2 M | 18.8 M | 22 M | 30.5 M | 20.6 M | 24.8 M | 21.3 M | 20.6 M | 19.7 M | 19.4 M | 20.1 M | 17.4 M | 15.7 M | 15 M | 11.9 M | 12.4 M | 11.5 M | 12.3 M | 10.7 M | 10.3 M | 10.5 M | 11.1 M | 11.4 M | 11.8 M | 11.8 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 140 M | 10.3 M | 39.5 M |
Operating Expenses of other stocks in the Biotechnology industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Repare Therapeutics
RPTX
|
147 M | - | - | $ 112 M | ||
|
Sesen Bio
SESN
|
81.8 M | - | 7.29 % | $ 127 M | ||
|
Windtree Therapeutics
WINT
|
26.1 M | - | - | $ 26.8 M | ||
|
Trean Insurance Group
TIG
|
-121 K | - | - | $ 316 M | ||
|
SQZ Biotechnologies Company
SQZ
|
102 M | - | 57.95 % | $ 12.8 M | ||
|
MEI Pharma
MEIP
|
17.5 M | - | 10.43 % | $ 20.5 M | ||
|
Palatin Technologies
PTN
|
21.9 M | - | - | $ 13 M | ||
|
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - | ||
|
Lyra Therapeutics
LYRA
|
31.4 M | - | - | $ 24.9 M | ||
|
Brickell Biotech
BBI
|
14.4 M | - | -5.38 % | $ 6.06 M | ||
|
Applied Therapeutics
APLT
|
105 M | - | - | $ 8.42 M | ||
|
ESSA Pharma
EPIX
|
34.4 M | - | - | $ 8.86 M | ||
|
Generation Bio Co.
GBIO
|
162 M | - | - | $ 344 M | ||
|
Clearside Biomedical
CLSD
|
33.1 M | - | - | $ 25.3 M | ||
|
Merus N.V.
MRUS
|
308 M | - | - | $ 5.78 B | ||
|
RAPT Therapeutics
RAPT
|
136 M | - | - | $ 2.36 B | ||
|
Annexon
ANNX
|
216 M | $ 3.11 | -8.94 % | $ 482 M | ||
|
Acasti Pharma
ACST
|
11.1 M | - | 4.01 % | $ 150 M | ||
|
Aptose Biosciences
APTO
|
24.7 M | - | -45.71 % | $ 1.2 M | ||
|
Galapagos NV
GLPG
|
787 M | - | - | $ 1.83 B | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
754 K | - | -4.36 % | $ 27 M | ||
|
Avenue Therapeutics
ATXI
|
4.49 M | - | -52.27 % | $ 4.45 M | ||
|
Galmed Pharmaceuticals Ltd.
GLMD
|
8.51 M | $ 4.63 | 21.05 % | $ 20 M | ||
|
Achieve Life Sciences
ACHV
|
16.5 M | $ 6.78 | 0.89 % | $ 296 M | ||
|
Leap Therapeutics
LPTX
|
41.1 M | - | 368.57 % | $ 41.9 M | ||
|
Lumos Pharma
LUMO
|
38.7 M | - | - | $ 35.3 M | ||
|
Gamida Cell Ltd.
GMDA
|
48.2 M | - | -18.25 % | $ 5.04 M | ||
|
Axcella Health
AXLA
|
77 M | - | -16.42 % | $ 249 M | ||
|
Metacrine
MTCR
|
61.1 M | - | - | $ 24.2 M | ||
|
Zealand Pharma A/S
ZEAL
|
1.23 B | - | 0.52 % | $ 821 M | ||
|
Myovant Sciences Ltd.
MYOV
|
187 M | - | -0.04 % | $ 2.62 B | ||
|
Bellerophon Therapeutics
BLPH
|
22.4 M | - | -74.18 % | $ 955 K | ||
|
Idera Pharmaceuticals
IDRA
|
32.7 M | - | -23.04 % | $ 26.6 M | ||
|
Akero Therapeutics
AKRO
|
285 M | - | - | $ 3.67 B | ||
|
Verona Pharma plc
VRNA
|
197 M | - | - | $ 69.7 B | ||
|
Atreca
BCEL
|
98.7 M | - | -11.76 % | $ 5.79 M | ||
|
Guardion Health Sciences
GHSI
|
9.73 M | - | -0.31 % | $ 3.64 M | ||
|
Opiant Pharmaceuticals
OPNT
|
42.6 M | - | - | $ 109 M | ||
|
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | ||
|
ImmunoGen
IMGN
|
330 M | - | - | $ 7.92 B | ||
|
Vascular Biogenics Ltd.
VBLT
|
14.8 M | - | -8.77 % | $ 12.4 M | ||
|
Cidara Therapeutics
CDTX
|
177 M | - | - | $ 1.41 B | ||
|
Iterum Therapeutics
ITRM
|
18.7 M | - | - | $ 591 K | ||
|
Virpax Pharmaceuticals
VRPX
|
12.1 M | - | -45.12 % | $ 2.85 M | ||
|
Navidea Biopharmaceuticals
NAVB
|
13.9 M | - | -2.99 % | $ 2.47 M | ||
|
Stealth BioTherapeutics Corp
MITO
|
46.3 M | - | - | $ 23.9 M | ||
|
OncoSec Medical Incorporated
ONCS
|
37 M | - | 31.87 % | $ 1.61 M |